Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

Safe and Timely Antithrombotic Removal (STAR) Registry

← catalyst calendar

NCT05077124

Sponsored by CytoSorbents, Inc (industry) · CTSO — their whole pipeline →.

Phase
Status
Recruiting
Study type
Observational
Enrollment
1,000estimated
Sites
30
Countries
Austria, Belgium, Germany +3

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2021-09-30actualWhen the study began enrolling
Primary completion2025-09-30estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completion2025-09-30estimatedThe whole study's end, after follow-up
First posted2021-10-14actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2025-07-16actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

  • Hemorrhage, Surgical
  • Hemorrhage Postoperative
  • Blood Loss, Surgical
  • Blood Loss, Postoperative

Intervention

  • Device: CytoSorb

Primary outcome

what the primary-completion date above is the date OF
Bleeding complications including requirements for transfusions and other blood products
measured Assessed until postoperative day (POD) 3, date of ICU discharge, or date of death, whatever comes first; on average 3 days

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · CTSO's whole pipeline · Catalyst calendar · Every registered study · What changed